Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk

To evaluate whether the prescription of SGLT2-inhibitors in primary care patients with type 2 diabetes (T2DM) and a very high risk was according to the newest updated Dutch general practitioners ’ practice guidelines on T2DM.

Source: Primary Care Diabetes - February 11, 2023 Category: Primary Care Authors: Hubert E. Hart, Olivier Kievits, Frans H. Rutten, Monika H. Hollander Source Type: research